Information Provided By: 
Fly News Breaks for June 10, 2016
PRTA
Jun 10, 2016 | 07:10 EDT
RBc Capital believes that the Phase I data for Prothena's antibody program, '003, was positive. The firm thinks the treatment "could be a new psoriasis drug or go after other big inflammatory markets." The firm expects '003 to begin to get attention from investors, and it views the product as "somewhat de-risked." RBC keeps an Outperform rating on the shares.
News For PRTA From the Last 2 Days
There are no results for your query PRTA
